{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:13:47Z","timestamp":1789820027534,"version":"4.0.1"},"reference-count":29,"publisher":"Bioscientifica","issue":"1","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>Lynch syndrome is the result of pathogenic variants in mismatch repair genes that increase the risk of cancer, including adrenocortical carcinoma. Little is known, however, about the clinical characteristics of patients with Lynch syndrome-associated adrenocortical carcinoma. In order to understand the clinical characteristics and prevalence of Lynch syndrome-associated adrenocortical carcinoma, we conducted a retrospective chart review of patients with adrenocortical carcinoma and germline genetic testing results, indicating pathogenic variants in mismatch repair genes consistent with Lynch syndrome at a single academic tertiary-care institution. In total, 21 patients with Lynch syndrome-associated adrenocortical carcinoma were identified from 2003 to 2024. Three patients met Amsterdam I criteria, and 12 patients met Amsterdam II criteria (including adrenocortical carcinoma as a Lynch syndrome-associated cancer). More than 90% of patients with available histopathology had high-grade tumors, suggesting a more aggressive nature. The prevalence of Lynch syndrome-associated adrenocortical carcinoma is estimated at 2.6%. This study further demonstrates that adrenocortical carcinoma is a Lynch syndrome-associated cancer and may be associated with a high-grade disease. Furthermore, our findings suggest that further research should be pursued to investigate the potential utility of immunotherapy for adrenocortical carcinoma, especially in the presence of microsatellite instability.<\/jats:p>","DOI":"10.1530\/erc-25-0389","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T14:47:54Z","timestamp":1768229274000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence and clinical characteristics of Lynch syndrome-associated adrenocortical carcinoma"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3029-6941","authenticated-orcid":true,"given":"Avilasha","family":"Sinha","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-8248","authenticated-orcid":true,"given":"Katherine I","family":"Wolf","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenae","family":"Osborne","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Hesseltine","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis P","family":"Worden","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Giordano","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D","family":"Hammer","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2262-0011","authenticated-orcid":true,"given":"Tobias","family":"Else","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2026070909453933400_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10689-013-9637-8","article-title":"The history of Lynch syndrome","volume":"12","author":"Boland","year":"2013","journal-title":"Fam Cancer"},{"key":"2026070909453933400_bib2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10147-019-01494-y","article-title":"Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome","volume":"24","author":"Tamura","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2026070909453933400_bib3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.gim.2022.01.014","article-title":"Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: systematic review and meta-analysis","volume":"24","author":"Abu-Ghazaleh","year":"2022","journal-title":"Genet Med"},{"key":"2026070909453933400_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/tog.12706","article-title":"Lynch syndrome for the gynaecologist","volume":"23","author":"Ryan","year":"2021","journal-title":"Obstet Gynaecol"},{"key":"2026070909453933400_bib5","volume-title":"StatPearls","author":"Bhattacharya","year":"2024"},{"key":"2026070909453933400_bib6","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a Lynch syndrome\u2013associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070909453933400_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/pbc.20318","article-title":"Biology, clinical characteristics, and management of adrenocortical tumors in children","volume":"45","author":"Rodriguez-Galindo","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"2026070909453933400_bib8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1086\/302575","article-title":"Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors","volume":"65","author":"Varley","year":"1999","journal-title":"Am J Hum Genet"},{"key":"2026070909453933400_bib9","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/jnci\/86.22.1707","article-title":"High frequency of germline p53 mutations in childhood adrenocortical cancer","volume":"86","author":"Wagner","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"2026070909453933400_bib10","article-title":"Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma","volume":"205","author":"Scatolini","year":"2024","journal-title":"Eur J Cancer Oxf Engl"},{"key":"2026070909453933400_bib11","doi-asserted-by":"crossref","first-page":"E476","DOI":"10.1210\/jc.2011-1982","article-title":"TP53 germline mutations in adult patients with adrenocortical carcinoma","volume":"97","author":"Herrmann","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909453933400_bib12","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1007\/s00268-009-9983-8","article-title":"Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value","volume":"33","author":"Waldmann","year":"2009","journal-title":"World J Surg"},{"key":"2026070909453933400_bib13","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00268-002-6492-4","article-title":"Adrenal involvement in multiple endocrine neoplasia type 1","volume":"26","author":"Langer","year":"2002","journal-title":"World J Surg"},{"key":"2026070909453933400_bib14","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJM198604173141603","article-title":"Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms","volume":"314","author":"S\u00f8rensen","year":"1986","journal-title":"N Engl J Med"},{"key":"2026070909453933400_bib15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/imj.1967.16.3.242","article-title":"Gardner\u2019s syndrome with adrenal carcinoma","volume":"16","author":"Marshall","year":"1967","journal-title":"Australas Ann Med"},{"key":"2026070909453933400_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0046-8177(98)90052-1","article-title":"Adrenocortical tumor in a patient with familial adenomatous polyposis: a case associated with a complete inactivating mutation of the APC gene and unusual histological features","volume":"29","author":"Wakatsuki","year":"1998","journal-title":"Hum Pathol"},{"key":"2026070909453933400_bib17","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/1097-0142(19850501)55:9<2001::AID-CNCR2820550929>3.0.CO;2-7","article-title":"Adrenal adenomas and adrenal carcinomas in association with hereditary adenomatosis of the colon and rectum","volume":"55","author":"Painter","year":"1985","journal-title":"Cancer"},{"key":"2026070909453933400_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mce.2011.12.008","article-title":"Association of adrenocortical carcinoma with familial cancer susceptibility syndromes","volume":"351","author":"Else","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2026070909453933400_bib19","volume-title":"StatPearls","author":"Torti","year":"2023"},{"key":"2026070909453933400_bib20","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1210\/jc.2012-2198","article-title":"Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma","volume":"98","author":"Raymond","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909453933400_bib21","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s40618-020-01306-5","article-title":"The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature","volume":"43","author":"Brabo","year":"2020","journal-title":"J Endocrinol Investig"},{"key":"2026070909453933400_bib22","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3390\/cancers16050900","article-title":"The efficacy and safety of immune checkpoint inhibitors in adrenocortical carcinoma: a systematic review and meta-analysis","volume":"16","author":"Ababneh","year":"2024","journal-title":"Cancers"},{"key":"2026070909453933400_bib23","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6072863","article-title":"Molecular drivers of potential immunotherapy failure in adrenocortical carcinoma","volume":"2019","author":"Fiorentini","year":"2019","journal-title":"J Oncol"},{"key":"2026070909453933400_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2024.112272","article-title":"Cellular landscape of adrenocortical carcinoma at single-nuclei resolution","volume":"590","author":"Tourigny","year":"2024","journal-title":"Mol Cell Endocrinol"},{"key":"2026070909453933400_bib25","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070909453933400_bib26","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.2012.13088","article-title":"Identification of Lynch syndrome among patients with colorectal cancer","volume":"308","author":"Moreira","year":"2012","journal-title":"JAMA"},{"key":"2026070909453933400_bib27","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1056\/NEJMoa053493","article-title":"Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer","volume":"354","author":"Barnetson","year":"2006","journal-title":"N Engl J Med"},{"key":"2026070909453933400_bib28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1210\/clinem\/dgaa833","article-title":"Characteristics of adrenocortical carcinoma associated with Lynch syndrome","volume":"106","author":"Dom\u00e8nech","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909453933400_bib29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1530\/ERC-21-0040","article-title":"Targeted genomic analysis of 364 adrenocortical carcinomas","volume":"28","author":"Pozdeyev","year":"2021","journal-title":"Endocr Relat Cancer"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/1\/ERC-25-0389.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/1\/ERC-25-0389.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0389\/505943\/erc-25-0389.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0389\/505943\/erc-25-0389.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:45:45Z","timestamp":1783604745000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/1\/e250389\/75562\/Prevalence-and-clinical-characteristics-of-Lynch"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0389","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e250389"}}